The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta‐analysis of randomized‐controlled clinical trials
Open accessAbstract
BACKGROUND: The overall clinical efficacy of the azoles antifungal agents and low‐dose intravenous amphotericin B for antifungal chemoprophylaxis in patients with malignant disease who have severe neutropenia remains unclear. METHODS: Randomized‐controlled trials of azoles (fluconazole, itraconazole, ketoconazole, and miconazole) or intravenous amphotericin B formulations compared with placebo/no treatment or polyene‐based controls in severely neutropenic chemotherapy recipients were evaluated using meta‐analytical techniques. RESULTS: Thirty‐eight trials that included 7014 patients (study agents, 3515 patients; control patients, 3499 patients) were analyzed. Overall, there were reductions in the use of parenteral antifungal therapy (prophylaxis success: odds ratio [OR], 0.57; 95% confidence interval [95% CI], 0.48–0.68; relative risk reduction [RRR], 19%; number requiring treatment for this outcome [NNT], 10 patients), superficial fungal infection (OR, 0.29; 95% CI, 0.20–0.43; RRR, 61%; NNT, 12 patients), invasive fungal infection (OR, 0.44; 95% CI, 0.35–0.55; RRR, 56%; NNT, 22 patients), and fungal infection‐related mortality (OR, 0.58; 95% CI, 0.41–0.82; RRR, 47%; NNT, 52 patients). Invasive aspergillosis was unaffected (OR, 1.03; 95% CI, 0.62–1.44). Although overall mortality was not reduced (OR, 0.87; 95% CI, 0.74–1.03), subgroup analyses showed reduced mortality in studies of patients who had prolonged neutropenia (OR, 0.72; 95% CI, 0.55–0.95) or who underwent hematopoietic stem cell transplantation (HSCT) (OR, 0.77; 95% CI, 0.59–0.99). The multivariate metaregression analyses identified HSCT, prolonged neutropenia, acute leukemia with prolonged neutropenia, and higher azole dose as predictors of treatment effect. CONCLUSIONS: Antifungal prophylaxis reduced morbidity, as evidenced by reductions in the use of parenteral antifungal therapy, superficial fungal infection, and invasive fungal infection, as well as reducing fungal infection‐related mortality. These effects were most pronounced in patients with malignant disease who had prolonged neutropenia and HSCT recipients. Cancer 2002;94:3230–46. © 2002 American Cancer Society. DOI 10.1002/cncr.10610
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
The Handbook of Research Synthesis.
Light, R. J., Cooper, H., & Hedges, L. V. (1994) · Journal of the American Statistical Association · doi:10.2307/2291021 · Cited by 1,868
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681 · cited 1×
“, the reduction of adverse events achieved by a treatment, expressed as a proportion of the control rate; the formula is [event rate, control group event rate, study group]/ event rate, control group) and the number of patients who required treatment to prevent or promote a particular outcome compared with control par…”
MethodMeta-Analysis in Clinical Research
L'ABBÉ, K. A., DETSKY, A. S., & O'ROURKE, K. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-2-224 · Cited by 1,267 · cited 1×
“, the reduction of adverse events achieved by a treatment, expressed as a proportion of the control rate; the formula is [event rate, control group event rate, study group]/ event rate, control group) and the number of patients who required treatment to prevent or promote a particular outcome compared with control par…”
MethodMeta-Analyses of Randomized Controlled Trials
Sacks, H. S., Berrier, J., Reitman, D., Ancona-Berk, V. A., & Chalmers, T. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702193160806 · Cited by 1,250
Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H., Shadduck, R. K., Shea, T. C., Stiff, P., Friedman, D. J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203263261301 · Cited by 1,174
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Self-citationWingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Slavin, M. A., Osborne, B., Adams, R., Levenstein, M. J., Schoch, H. G., Feldman, A. R., Meyers, J. D., & Bowden, R. A. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/171.6.1545 · Cited by 820
GERSON, S. L., TALBOT, G. H., HURWITZ, S., STROM, B. L., LUSK, E. J., & CASSILETH, P. A. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-100-3-345 · Cited by 763
Bone Marrow Transplants from Unrelated Donors for Patients with Chronic Myeloid Leukemia
Hansen, J. A., Gooley, T. A., Martin, P. J., Appelbaum, F., Chauncey, T. R., Clift, R. A., Petersdorf, E. W., Radich, J., Sanders, J. E., Storb, R. F., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804023381405 · Cited by 570
Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542 · cited 1×
“There has been concern that antifungal prophylaxis with agents like fluconazole would lead to a selection for and infection by azole-resistant fungi.(55,106,107) This has not been observed in clinical practice, however.”
BackgroundMarr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E. D., Corey, L., & Boeckh, M. (2000) · Blood · doi:10.1182/blood.v96.6.2055 · Cited by 511
Champlin, R. E., Schmitz, N., Horowitz, M. M., Chapuis, B., Chopra, R., Cornelissen, J. J., Gale, R. P., Goldman, J. M., Loberiza, F. R., Hertenstein, B., et al. (2000) · PubMed · doi:10.1182/blood.v95.12.3702 · Cited by 507
Marr, K. A., Seidel, K., White, T. C., & Bowden, R. A. (2000) · The Journal of Infectious Diseases · doi:10.1086/315193 · Cited by 493
(1994) · Cited by 463
BONE MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Ansen, J. O. A. H., Ooley, A. G., Artin, P. A. J. M., et al. (1998) · Cited by 400
Hedges, L. V. (1994) · Cited by 397
Winston, D. J., Chandrasekar, P. H., Lazarus, H. M., Goodman, J. L., Silber, J. L., Horowitz, H., Shadduck, R. K., Rosenfeld, C. S., Ho, W. G., Islam, M. Z., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00003 · Cited by 373
Impact of air filtration on nosocomial aspergillus infections
Sherertz, R. J., Belani, A., Kramer, B. S., Elfenbein, G. J., Weiner, R. S., Sullivan, M. L., Thomas, R. G., & Samsa, G. P. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90902-8 · Cited by 333
SCHIMPFF, S. C., GREENE, W. H., YOUNG, V. M., FORTNER, C. L., JEPSEN, L., CUSACK, N., BLOCK, J. B., & WIERNIK, P. H. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-351 · Cited by 327
Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00010 · Cited by 321
Self-citationPredictors of Adverse Outcome in Cancer Patients with Candidemia
Anaissie, E. J., Rex, J. H., Uzun, Ö., & Vartivarian, S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00030-8 · Cited by 295
Invasive Aspergillosis in Acute Leukemia: Correlation with Nose Cultures and Antibiotic Use
AISNER, J., MURILLO, J., SCHIMPFF, S. C., & STEERE, A. C. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-90-1-4 · Cited by 271
Rotstein, C., Bow, E. J., Laverdiere, M., Ioannou, S., Carr, D., Moghaddam, N., & The Canadian Fluconazole Prophylaxis Study Group (1999) · Clinical Infectious Diseases · doi:10.1086/515128 · Cited by 265
Self-citationIncidence and risk factors for invasive fungal infections in allogeneic BMT recipients
Jantunen, E., Ruutu, P., Niskanen, L., Volin, L., Parkkali, T., Koukila-Kähkölä, P., & Ruutu, T. (1997) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1700737 · Cited by 251
Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C., Barbabietola, G., Pagano, L., Leoni, P., Specchia, G., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/515129 · Cited by 244 · cited 1×
“Control Plac/AmB-PO 47 /4000 mg 45 0 2 25 80 Menichetti et al.(74) (0)”
Goodrich, J. M., Reed, E. C., Mori, M., Fisher, L. D., Skerrett, S., Dandliker, P. S., Klis, B., Counts, G. W., & Meyers, J. D. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/164.4.731 · Cited by 214
Morgenstern, G. R., Prentice, A. G., Grant Prentice, H., Ropner, J. E., Schey, S. A., Warnock, D. W., & on behalf of the U.K. Multicentre Antifungal Prophylaxis Study Group (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01465.x · Cited by 201
Bow, E. J., Loewen, R., Cheang, M. S., & Schacter, B. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/21.2.361 · Cited by 181
Self-citationKelsey, S., Goldman, J., McCann, S., Newland, A., Scarffe, J., Oppenheim, B., & Mufti, G. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701543 · Cited by 173
Prophylactic Intravenous Amphotericin B in Neutropenic Autologous Bone Marrow Transplant Recipients
Perfect, J. R., Klotman, M. E., Gilbert, C. C., Crawford, D. D., Rosner, G. L., Wright, K. A., & Peters, W. P. (1992) · Journal of Infectious Diseases · doi:10.1093/infdis/165.5.891 · Cited by 171
Tollemar, J. G., Ringdén, O. T. H., Andersson, S., Sundberg, B., Ljungman, P. T., & Tydén, G. (1993) · PubMed · Cited by 162
Thicot, G., Joosten, E., Boogaerts, M. A., Vande Pitte, J., & Cauwenbergh, G. (1987) · Clinical Infectious Diseases · doi:10.1093/clinids/9.supplement_1.s94 · Cited by 162
DeGregorio, M. W., Lee, W. M. F., & Ries, C. A. (1982) · Cancer · doi:10.1002/1097-0142(19821215)50:12<2780::aid-cncr2820501215>3.0.co;2-p · Cited by 156
Prophylactic action of oral fluconazole against fungal infection in neutropenic patients
Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., Matsuyama, T., Takezako, N., Miwa, A., Kern, W., et al. (2000) · Cancer · doi:10.1002/1097-0142(20001001)89:7<1611::aid-cncr27>3.0.co;2-b · Cited by 154
Harousseau, J., Dekker, A. W., Stamatoullas, A., Fassas, Α., Linkesch, W., Gouveia, J., Bock, R. D., Rovira, M., Seifert, W., Joosen, H., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1887-1893.2000 · Cited by 151
Hann, I. M., Corringham, R. E., Keaney, M. G. L., Noone, P., Fox, J., Szawatkowski, M., Prentice, H. G., Blacklock, H. A., Shannon, M. S., Gascoigne, E. W., et al. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91874-8 · Cited by 150
Control of Construction-Associated Nosocomial Aspergillosis in an Antiquated Hematology Unit
Loo, V. G., Bertrand, C., Dixon, C., Vityé, D., DeSalis, B., McLean, A. P. H., Brox, A. G., & Robson, H. G. (1996) · Infection Control and Hospital Epidemiology · doi:10.1086/647317 · Cited by 147
Menichetti, F., Favero, A. D., Martino, P., Bucaneve, G., Micozzi, A., D'Antonio, D., Ricci, P., Carotenuto, M., Liso, V., Nosari, A. M., et al. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-11-199406010-00003 · Cited by 139
Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., Matsuyama, T., Takezako, N., Miwa, A., Kern, W., et al. (2000) · PubMed · Cited by 137
Rousey, S. R., Russler, S. K., Gottlieb, M. S., & Ash, R. C. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90184-y · Cited by 137
Bodey, G. P., Anaissie, E. J., Elting, L. S., Estey, E. H., O'Brien, S. M., & Kantarjian, H. M. (1994) · Cancer · doi:10.1002/1097-0142(19940415)73:8<2099::aid-cncr2820730814>3.0.co;2-n · Cited by 127
Schaffner, A., & Schaffner, M. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.4.1035 · Cited by 120
Philpott‐Howard, J., Wade, J. J., Mufti, G. J., Brammer, K. W., & Ehniniger, G. (1993) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/31.6.973 · Cited by 113
Nucci, M., Biasoli, I., Akiti, T., Silveira, F., Solza, C., Barreiros, G., Spector, N., Derossi, A., & Pulcheri, W. (2000) · Clinical Infectious Diseases · doi:10.1086/313654 · Cited by 113
The prophylactic use of low-dose amphotericin B in bone marrow transplant patients
Riley, D. K., Pavia, A. T., Beatty, P. G., Petersen, F. B., Spruance, J. L., Stokes, R., & Evans, T. G. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90345-x · Cited by 112
Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal [see comments]
Uzun, Ö., & Anaissie, E. (1995) · Blood · doi:10.1182/blood.v86.6.2063.bloodjournal8662063 · Cited by 107
Gotzsche, P. C., & Johansen, H. (1997) · BMJ · doi:10.1136/bmj.314.7089.1238 · Cited by 105
Ninane, J. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01974614 · Cited by 103
Chemoprophylaxis of fungal infections
Meunier-Carpentier, F. (1984) · The American Journal of Medicine · doi:10.1016/0002-9343(84)90290-0 · Cited by 100
Ellis, M. E., Clink, H. M., Ernst, P., Halim, M. A., Padmos, A., Spence, D. J., Kalin, M., Qadri, S. M. H., Burnie, J., & Greer, W. (1994) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02026116 · Cited by 96
Wingard, J. R., Vaughan, W. P., Braine, H., Merz, W. G., & Saral, R. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90949-1 · Cited by 95
Vreugdenhil, G., van Dijke, B. J., Donnelly, J. P., Nováková, I. R. O., Raemaekers, J. M. M., Hoogkamp-Korstanje, M. A. A., Koster, M., & Pauw, B. E. D. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309067926 · Cited by 94
Prophylaxis of Oropharyngeal Candidiasis with Fluconazole
Samonis, G., Rolston, K. V. I., Karl, C. L., Miller, P., & Bodey, G. P. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s369 · Cited by 91
Chemotherapy for multiple myeloma
Alexanian, R., & Dreicer, R. (1984) · Cancer · doi:10.1002/1097-0142(19840201)53:3<411::aid-cncr2820530308>3.0.co;2-e · Cited by 90
Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients
Laverdière, M., Rotstein, C., Bow, E. J., Roberts, R. S., Ioannou, S., Carr, D., & Moghaddam, N. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.6.1001 · Cited by 82
Self-citationRozenberg-Arska, M., Dekker, A. W., Branger, J., & Verhoef, J. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/27.3.369 · Cited by 79
Shepp, D. H., Klosterman, A. M., Siegel, M. S., & Meyers, J. D. (1985) · The Journal of Infectious Diseases · doi:10.1093/infdis/152.6.1257 · Cited by 76
THE PROTEASE‐ACTIVATED RECEPTORS AND THEIR CELLULAR EXPRESSION AND FUNCTION IN BLOOD‐RELATED CELLS
Hou, Howells, Kapas, & Macey (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00696.x · Cited by 74
Prentice, A. G., Warnock, D. W., Johnson, S. A., Taylor, P. C., & Oliver, D. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.4.657 · Cited by 74
Timmers, G. J., Zweegman, S., Simoons‐Smit, A. M., Loenen, A. C. V., Touw, D. J., & Huijgens, P. C. (2000) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1702243 · Cited by 70
Efficacy of ketoconazole v nystatin in prevention of fungal infections in neutropenic patients.
Jones, P. G., Kauffman, C. A., McAuliffe, L. S., Liepman, M. K., & Bergman, A. G. (1984) · PubMed · Cited by 63
German AML Cooperative Group, Kern, W., Behre, G., Rudolf, T., Kerkhoff, A., Grote‐Metke, A., Eimermacher, H., Kubica, U., Wormann, B. J., B�chner, T., et al. (1998) · Cancer · Cited by 62
The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients
Chandrasekar, P. H., & Gatny, C. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.2.309 · Cited by 62
Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia
Glasmacher, A. G., Molitor, E., Hahn, C., Bomba, K., Ewig, S., Leutner, C., Wardelmann, E., Schmidt‐Wolf, I. G. H., Mezger, J. M., Marklein, G., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401137 · Cited by 58
Antifungal Prophylaxis in Bone Marrow Transplantation
Milliken, S., & Powles, R. L. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s374 · Cited by 55
Effect of Fluconazole Prophylaxis on Fever and Use of Amphotericin in Neutropenic Cancer Patients
Chandrasekar, P. H., Gatny, C. M., & Bone Marrow Transplantation Team (2009) · Chemotherapy · doi:10.1159/000239184 · Cited by 50
Alangaden, G. J., Chandrasekar, P. H., Bailey, E., & Khaliq, Y. (1994) · PubMed · Cited by 49
CATHETER-RELATED COMPLICATIONS OF CANCER THERAPY
Greene, J. N. (1996) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70299-3 · Cited by 49
Böhme, A., Just‐Nübling, G., Bergmann, L., SHAH, P. M., Stille, W., & Hoelzer, D. T. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.6.953 · Cited by 49
Todeschini, G., Murari, C., Bonesi, R., Pizzolo, G., Amaddi, G., Ambrosetti, A., Cerù, S., Piacentini, I., Martini, N., Montresor, P., et al. (1993) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01973640 · Cited by 48
Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants
Epstein, J. B., Ransier, A., Lunn, R., Chin, E., Jacobson, J. J., Le, N. D., & Reece, D. E. (1996) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/s1079-2104(96)80328-3 · Cited by 48
Efficacy of different prophylactic antifungal regimens in bone marrow transplantation.
Annaloro, C., Oriana, A., Tagliaferri, E., Bertolli, V. G., Volpe, A. D., Soligo, D. A., Ibatici, A., Pozzoli, E. F., & Deliliers, G. L. (1995) · PubMed · Cited by 48
Efficacy of Ketoconazole v Nystatin in Prevention of Fungal Infections in Neutropenic Patients
Jones, P. G. (1984) · Archives of Internal Medicine · doi:10.1001/archinte.1984.00350150149034 · Cited by 48
Groll, A. H. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.6.855 · Cited by 46
Palmblad, J. E. W., Lönnqvist, B., Carlsson, B., Grimfors, G., Järnmark, M., Lerner, R., Ljungman, P. T., Nyström-Rosander, C., Petrini, B., & Öberg, G. (1992) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1992.tb00945.x · Cited by 45
Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients.
Thunnissen, P. L. M., Sizoo, W., & Hendriks, W. D. H. (1991) · PubMed · Cited by 44
Management of Fungal Infection in Neutropenic Patients with Fluconazole
Brammer, K. W. (1990) · Hämatologie und Bluttransfusion · doi:10.1007/978-3-642-74643-7_97 · Cited by 40
Egger, T., Gratwohl, A. A., Tichelli, A., Uhr, M., Gysi, C. S., Passweg, J. R., Pless, M., Wernli, M., Buser, U., Wuhrmann, J., et al. (1995) · Supportive Care in Cancer · doi:10.1007/bf00365855 · Cited by 39
Prophylaxis of Fungal Infections with Itraconazole during Remission‐Induction Therapy
Prentice, A., & Bradford, G. R. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02298.x · Cited by 38
Benhamou, E., Hartmann, O., Noguès, C., Maraninchi, D., Valteau‐Couanet, D., & Lemerle, J. (1991) · PubMed · Cited by 31
Akiyama, H., Mori, S., Tanikawa, S., Sakamaki, H., & ONOZAWA, Y. (1993) · Mycoses · doi:10.1111/j.1439-0507.1993.tb00725.x · Cited by 26
Finke, R. (1990) · Mycoses · doi:10.1111/myc.1990.33.1s.42 · Cited by 21
Schulman, J. D., Agarwal, B., Sh, M., & Nr, S. (1978) · New England Journal of Medicine · doi:10.1056/nejm197809212991212 · Cited by 20
Schaison, G., Baruchel, A., & Arlet, G. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb07931.x · Cited by 18
Fluconazole prophylaxis and Candida fungemia in neutropenic children with malignancies.
Cesaro, S., Rossetti, F., Perilongo, G., et al. (1994) · PubMed · Cited by 16
Quirk, P. C., Osborne, P. J., & Walsh, L. J. (1995) · Australian Dental Journal · doi:10.1111/j.1834-7819.1995.tb04807.x · Cited by 6
Cited by
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer
Hughes, W. T., Armstrong, D., Bodey, G. P., Bow, E. J., Brown, A. E., Calandra, T., Feld, R., Pizzo, P. A., Rolston, K. V. I., Shenep, J. L., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339215 · Cited by 1,964
Self-citation
Metadata
- Authors
- Bow, E. J., Laverdière, M., Lussier, N., Rotstein, C., Cheang, M. S., & Ioannou, S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2002-06-12
- Volume
- 94
- Issue
- 12
- Pages
- 3230-3246
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1976941151
- Cited by
- 258
- References
- 91
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.